Trial Results Support Transition into Late-Stage Development with Program Expected to be Phase 2b/3-ready in H2 2026 BERLIN, GERMANY, January 29, 2026 – OMEICOS, a clinical-stage biopharmaceutical ...
Abstract: High-phase-count machines are well known to have reduced dc bus utilization compared to conventional three-phase drives. High-phase-count machines for fault tolerance and variable-pole ...
Detailed price information for Corcept Therapeutics (CORT-Q) from The Globe and Mail including charting and trades.
Corvus Pharmaceuticals, Inc. jumps 165% on Phase 1 soquelitinib atopic dermatitis data; learn key efficacy, funding, and ...
The market is set for growth driven by bandwidth demands from advanced optics, data centers, and quantum networks. Integrated chips and phase-stable, low-voltage designs are pivotal as emerging ...
Maze Therapeutics uses its Compass genetics platform to advance kidney and obesity drugs, with MZE829 Phase 2 data due in 2026. Learn why MAZE stock is a strong buy.
A pair of phase 3 psoriasis studies of Alumis’ TYK2 inhibitor have hit their primary endpoints, setting the biotech up to file for approval of a potential challenger to Bristol Myers Squibb’s Sotyktu.
A phase 3 study of Zenas BioPharma's autoimmune disease candidate has hit its primary endpoint. But, with the result falling short of the bar Amgen set in another study, the biotech's stock halved in ...
Abstract: This paper proposes a novel radar jamming method based on an amplitude-phase hybrid modulation mechanism. Utilizing a dual-drive Mach-Zehnder modulator (DDMZM) for radar signal modulation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results